410 Medical develops innovative resuscitation technologies for emergency and critical care.

AN2 Therapeutics is a clinical-stage biotech company advancing novel small molecule therapeutics.

Atsena Therapeutics is a clinical-stage gene therapy company focused on reversing or preventing blindness from inherited retinal diseases

Avivomed is a Minneapolis-based medical device company developing next-generation neuromodulation therapies

CREATE Medicines is a clinical-stage biotechnology company pioneering a new class of in vivo immune programming therapies

CVRx develops an implantable system that delivers baroreflex activation therapy. IPO in June 2021 (NASDAQ: CVRX).

Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. Acquired by Aledade in January 2022.

Perfuse Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class therapies to improve retinal blood flow and treat ischemia-driven eye diseases.

RapidPulse is a medical device company developing an innovative, minimally invasive vascular system for treating acute ischemic stroke.

SafeRide Health is a healthcare technology and services company that improves access to care by coordinating non-emergency medical transportation for vulnerable populations.

Shattuck Labs is a clinical-stage biotechnology company advancing novel biologic medicines for inflammatory and immune-mediated diseases. IPO in October 2020 (NASDAQ: STTK)

Tune Therapeutics is a biotechnology innovator advancing a new class of epi-therapeutic medicines

The company’s lead drug has potential to be a game-changer in the treatment of HITT. Acquired by Cadrenal Therapeutics 2025

Vigil Neuroscience is a clinical-stage biotechnology company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.
